Close menu




April 24th, 2025 | 07:30 CEST

Germany Inc. as the last hope? Volkswagen, Bayer, Globex Mining

  • Mining
  • Gold
  • Electromobility
  • Pharma
Photo credits: pexels.com

Germany's economy is facing its third consecutive year of contraction. The automotive industry is struggling with competition from China, and Bayer is grappling with past acquisitions, looming tariffs, and other challenges. Now, Bayer shareholders are even being asked to inject new capital. Is the German industry working with politicians to find long-term solutions? Not a chance! The days of Germany Inc. seem to be over. We look at how investors can seize opportunities in this complex situation.

time to read: 3 minutes | Author: Nico Popp
ISIN: VOLKSWAGEN AG VZO O.N. | DE0007664039 , BAYER AG NA O.N. | DE000BAY0017 , GLOBEX MINING ENTPRS INC. | CA3799005093

Table of contents:


    Justin Reid, President and CEO, Troilus Gold Corp.
    "[...] Troilus has the potential to be an entire gold belt. All of our work to date points to this, and each drill hole makes the picture we have of the Troilus project much clearer. [...]" Justin Reid, President and CEO, Troilus Gold Corp.

    Full interview

     

    Germany Inc.: A proven concept for prosperity for all

    Little remains of the once proud Germany Inc. Between the 1970s and 1990s, German banks pulled the strings together with industry. There were cross-shareholdings between companies, and people from different sectors met on supervisory boards. In 1988, representatives of Deutsche Bank alone sat on 400 supervisory boards. Alongside Alfred Herrhausen, Hermann Josef Abs was particularly prominent in this context, serving on over twenty supervisory boards. Abs was even responsible for introducing an upper limit on mandates. Although Germany Inc. had to live with accusations of collusion even back then, this form of cooperation ensured long-term strategies and shielded German industry from foreign influence.

    Even though the former Germany Inc. has not existed since the beginning of globalization and the focus on shareholder value in the late 1990s, the question must be asked whether closer cooperation between German companies - possibly under political leadership - would not be appropriate again at this point. The German automotive industry is struggling with dwindling margins and declining market share in Asia. The energy transition is necessitating a profound transformation. The security transition requires investment and the repurposing of former industrial plants. Skilled workers are currently tied to ailing industries and would be more productive elsewhere.

    Supply of raw materials critical for Germany

    While companies like Volkswagen are bucking the trend and adopting the "China speed" they acquired in the Far East to develop new models and strategies, companies are still largely fighting their battles alone. Mercedes-Benz, BMW, Porsche, and Volkswagen remain more rivals than companions in adversity. Shareholders are now also being called upon to resolve the crisis at Bayer - which is still suffering from the overpriced Monsanto takeover and the glyphosate scandal - and to inject new capital. Given the challenges ahead, the future German government's plans for lower energy costs should only be seen as a starting point. Further steps are necessary. However, a form of state capitalism in which the federal government protects markets and creates reliable framework conditions for entire supply chains is still a long way off.

    For many years, one of the weak points of German industry has been the supply of raw materials. Since metal mining in Europe is challenging due to strict regulations and comprehensive protection of individual rights, German companies must import raw materials. However, since Donald Trump took office, the world has been divided into several camps – and Europe appears to hold the worst cards in this competitive situation. This is reason enough to get involved in promising projects at an early stage.

    Globex Mining bundles 250 raw material projects

    The raw materials conglomerate Globex Mining is unique in its approach. Instead of carrying out extensive exploration work itself, the Company acquires promising properties, develops them to a certain point, and then grants options or license agreements to other companies. These partners then carry out further exploration or development, while Globex benefits from royalties and equity stakes. Globex Mining has around 250 projects in its portfolio, including properties with a focus on gold and silver, but also copper, zinc, nickel, cobalt, lithium, vanadium, and rare earths.


    As Globex Mining invests exclusively in North America, the Company offers unparalleled access to mineral resources in secure jurisdictions. Synergies between companies in the Globex network are also conceivable – very much in the style of the former Germany Inc. Since last October, Globex Mining's share price has already gained around 50%. Stocks such as Volkswagen (+1.2%) and Bayer (-14.3%) cannot keep pace. Globex Mining shares are particularly interesting for investors who want to participate in promising raw material projects at an early stage and, at the same time, value a high degree of diversification.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Armin Schulz on May 14th, 2025 | 07:00 CEST

    Patents, partnerships & tumor strategies: How Novo Nordisk, BioNxt Solutions, and BioNTech are securing tomorrow's profits

    • Biotechnology
    • Biotech
    • Pharma

    The global pharmaceutical industry, once the epitome of stable investments, is undergoing radical change. While protectionist trade barriers are disrupting supply chains and causing stock market prices to plummet, companies are forecasting growth for the biotech and pharmaceutical industries, according to the industry study "Life Sciences Executives Flash Report." The crisis is turning out to be a laboratory of opportunities – those who prioritize digital therapies, mRNA technologies, or sustainable production models now could emerge as winners in a reorganized market. But which strategies are convincing? We take a closer look at Novo Nordisk, BioNxt Solutions, and BioNTech.

    Read

    Commented by André Will-Laudien on May 13th, 2025 | 07:20 CEST

    Defense out - Time to buy commodities! Hensoldt, Globex Mining, Barrick, Mutares, and Steyr

    • Mining
    • Gold
    • Defense
    • Investments

    That is how quickly market darlings can fall out of favor. Just last week, Rheinmetall & Co. were hitting record highs, but as of Monday, the euphoria came to a sudden halt. Trump agreed with China on lower tariffs, and Volodymyr Zelenskyy will travel to Turkey on Thursday to sit down with Russia's aggressor, Vladimir Putin. At the moment, this is still hard to believe. For the capital markets, however, this means a shift: out of defense and into high-tech and automotive stocks, the biggest winners of recent hours. The whole thing could be seen as a healthy rotation, as the major indices are at record levels, while tech and automotive stocks have corrected significantly in recent weeks. Once again, the cards are being reshuffled. For Globex Mining, the setback is suitable for medium-term follow-up purchases.

    Read

    Commented by Nico Popp on May 13th, 2025 | 07:10 CEST

    The fight against cancer as a billion-dollar opportunity: BioNTech, Merck, and Vidac Pharma

    • Biotechnology
    • Biotech
    • Pharma

    Cancer is the scourge of our time. However, significant progress has already been made in recent years. In addition to significantly improved traditional therapies, individualized treatment approaches such as immunotherapy are repeatedly proving successful in curing patients. This trend is set to continue. Experts such as the investors at Candriam and market researchers at Spherical Insights foresee enormous growth – the market for cancer drugs could see double-digit annual growth by the 2030s. Market leaders such as BioNTech and Merck, as well as insider tips like Vidac Pharma, stand to benefit.

    Read